Monday, February 21, 2022 8:00:34 AM
The Company's immune modulator IPF Immune™ coming to the U.S. market in March.
The Company's development of ITV-1 therapeutic for treating HIV.
The Company's production of anti- HIV Monoclonal Antibodies.
The Company's production of anti-SARS CoV-2 Monoclonal Antibodies.
The Company's planned production of Monoclonal Antibodies addressing animal viruses such as the Equine Infectious Anemia Virus, Feline Leukemia Virus, Feline Immunodeficiency Virus, Equine Herpesvirus (EHV), Koala Retrovirus (KoRV), and the Elephant Endotheliotropic Herpesvirus (EEHV).
The Company's Artificial Intelligence (A.I.) Platform including:
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
- MWRK Positions For High Growth In $3.5 Trillion Metaverse Market Popularized By META • InvestorsHub NewsWire • 05/03/2023 04:24:58 PM
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM